Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Research And Development Expense of $5.85 billion for the year ending 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +14.0% in Research And Development Expense from 2024 to 2025.
- This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), REGENERON PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 2,028.1%.
- Historical annual values: Fiscal year 2025: $5.85 billion | Fiscal year 2024: $5.13 billion | Fiscal year 2023: $4.44 billion | Fiscal year 2022: $3.59 billion | Fiscal year 2021: $2.86 billion | Fiscal year 2020: $2.65 billion | Fiscal year 2019: $2.45 billion | Fiscal year 2018: $1.47 billion | Fiscal year 2017: $2.08 billion | Fiscal year 2016: $2.05 billion | Fiscal year 2015: $1.62 billion | Fiscal year 2014: $1.27 billion | Fiscal year 2013: $859.95 million | Fiscal year 2012: $625.55 million | Fiscal year 2011: $529.51 million | Fiscal year 2010: $489.25 million | Fiscal year 2009: $398.76 million | Fiscal year 2008: $274.90 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: